Vanguard Capital Management
STIM icon

Vanguard Capital Management’s Neuronetics STIM Stock Holding History

Vanguard Capital Management’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.57M Buy
1,527,373
+20,276
+1% +$49.8K ﹤0.01% 3189
2026
Q2 		$1.96M Sell
1,507,097
-540,878
-26% -$787K ﹤0.01% 3431
2026
Q1 		$2.97M Buy
+2,047,975
New +$3.25M ﹤0.01% 3240

Other funds holding STIM

Madryn Asset Management
Madryn Asset Management New York $55.5M AUM 7.4% 1-Year Est. Return
Wexford Capital
Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Lane Generational
Lane Generational Dover, Massachusetts $111M AUM 16.63% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management's STIM Position: Q3 2026 in Review

Vanguard Capital Management increased its Neuronetics (STIM) stake by 1.3% in Q3 2026, buying an estimated $49.8K and bringing the position to 1,527,373 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Vanguard Capital Management first reported a position in STIM in Q1 2026 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold STIM as of Q3 2026.

  • Vanguard Capital Management held 1,527,373 shares of Neuronetics worth $3.57M as of Q3 2026.
  • Vanguard Capital Management bought 20,276 Neuronetics shares in Q3 2026, an estimated $49.8K.
  • Neuronetics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3189 holding.
  • Vanguard Capital Management first reported a position in Neuronetics in Q1 2026 and has held it in 3 quarters since.
  • 58 funds tracked by Wall St. Rank held Neuronetics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.